Most Read Articles
3 days ago
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Pearl Toh, Yesterday
Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.

Short-term PTT supplementation has no effect on platelet aggregation in metabolic syndrome

Tristan Manalac
21 Sep 2017

Short-term supplementation of palm-based tocotrienols and tocopherol (PTT) does not significantly impact platelet aggregation and activation, coagulation and inflammation in patients with metabolic syndrome, a new randomized controlled trial reveals.

“Our results implied the lack of clinically significant effect on platelet homeostasis with acute supplementation of PTT mixture,” said researchers.

In the study cohort of 32 metabolic syndrome patients, body weight remained relatively stable and no adverse events were reported over the study period. Fasting plasma tocotrienol was higher in the PTT group (n=16; 0.58±0.50 µg/mL) than in the placebo control group (n=16; 0.03±0.06 µg/mL; p<0.001). [Sci Rep 2017;7:11542]

After 14 days of PTT supplementation, there was no significant difference in adenosine diphosphate (ADP)-induced platelet aggregation reactivity between the PTT and placebo groups (290±50 vs 295±48 P2Y reactivity units [PRU] respectively; p=0.393) as measured by the VerifyNow P2Y12 assay.

Similarly, platelet aggregation reactivity induced by arachidonic acid was not significantly different between the PTT and placebo groups (p=0.763), yielding respective aspirin reactivity units (ARU) of 631±33 and 628±36, respectively.

In terms of acute response following supplementation, there were also no significant differences in postprandial ADP-induced (1.77±31.59 vs -4.79±26.11 PRU; p=0.408) and arachidonic acid-induced (-1.29±37.77 vs 0.45±35.63; p=0.776) platelet aggregation between the PTT and placebo groups.

In terms of secondary outcomes, there were no significant between-group differences in terms of levels of fibrinogen (p=0.865), activated glycoproteins (p=0.602), soluble E-selectin (p=0.715) and P-selectin (p=0.224), D-dimer (p=0.505) and high-sensitivity C-reactive protein (p=0.795).

Levels of plasminogen activator inhibitor type 1 (p=0.551), undercarboxylated osteocalcin (p=0.196) and soluble intracellular (p=0.629) and soluble vascular (p=0.210) cellular adhesion molecules 1 were also comparable between the two groups.

The current literature provides conflicting reports on the effect of tocotrienol supplements on the platelet aggregation induced by ADP. Some have shown significant inhibitory effects on aggregation, while others have shown no substantial effects. According to the authors, these discrepancies may have stemmed from the differences in methods and measurements used.

Researchers employed the VerifyNow P2Y12 cartridge system, which uses fibrinogen-coated beads, and a specific agonist to measure the platelet aggregation reactivity.

“Unlike previous studies, VerifyNow instrument, a fully automated cartridge-based instrument that measures platelet aggregation at a standardised condition with its cartridge-based design and at a fixed concentration of ADP, was used in current trial,” they said.

The study has several limitations. Among these are the short supplementation period and the potential interactions between tocopherol and tocotrienols, both of which could have confounded the findings.

“Information from this study would add value to health practitioners and this cohort intending to consume PTT mixture as supplements for a short period of time,” said researchers. “Nevertheless, their long-term effects on platelet function remained uncertain and should be warranted in future studies.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
The appropriate cutoff value in predicting combined cardiovascular outcomes in patients with type 2 diabetes (T2D) is 125 mm Hg for home morning systolic blood pressure (MSBP), suggests a new study.
06 Apr 2018

Female patients with coronary artery disease (CAD) have greater regression of coronary atherosclerosis than male patients despite a lower plaque burden at baseline, data from the GLAGOV trial have shown.

26 Apr 2018
Transcatheter aortic valve replacement (TAVR) in severe symptomatic aortic stenosis (AS) patients is superior to conventional surgical aortic valve replacement (SAVR) in terms of reducing life-threatening bleeding, new-onset atrial fibrillation and acute kidney injury, a recent meta-analysis has found.
Pearl Toh, Yesterday
Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion here at the Asian Pacific Society of Cardiology (APSC) Congress 2018 in Taiwan last week.